Oncolytics Biotech Inc. has announced the appointment of Dr. Jeremy Grushcow to the role of General Counsel.
Dr. Grushcow has more than ten years' experience in the legal profession representing public and private entities, as well as venture capital and private equity firms in the acquisition, financing, development, operation and sale of pharmaceutical and life sciences companies in the U.S. and Canada.
He holds a B.Sc. from the University of Toronto, a Ph.D. in molecular genetics and cell biology from the University of Chicago, and a J.D. with honors from the University of Chicago Law School.
He has been admitted to the Bar in Ontario, New York and Illinois. Prior to joining Oncolytics, Dr. Grushcow was a partner in the Norton Rose LLP pharmaceuticals and life sciences group.
He also previously held positions in the Shearman & Sterling LLP capital markets group and the Kirkland & Ellis LLP intellectual property transactions group.
"We are delighted to welcome Jeremy to our management team," said Dr. Brad Thompson, President and CEO of Oncolytics.
Dr. Thompson continued, "He brings a unique combination of scientific, legal and business expertise that will support Oncolytics' continued evolution and we look forward to benefiting from his specific experience and insight."